Key result
Angiotensin II stimulated biliary mass and proliferation in both normal and bile duct-ligated rats, while the angiotensin receptor blocker losartan attenuated bile duct ligation-induced biliary proliferation.
Why the study?
Does modulation of the renin-angiotensin system with Angiotensin II or losartan affect biliary proliferation and fibrosis in a rat model of extrahepatic cholestasis?
Does modulation of the renin-angiotensin system with Angiotensin II or losartan affect biliary proliferation and fibrosis in a rat model of extrahepatic cholestasis?
Cholangiocytes express a local renin-angiotensin system, and its activation by Angiotensin II stimulates biliary proliferation and fibrosis during extrahepatic cholestasis, which can be attenuated by losartan.
Supports renin-angiotensin modulation of biliary proliferation; hypothesis-generating and requires human studies before clinical consideration.
Cholangiocyte proliferation is regulated in a coordinated fashion by many neuroendocrine factors through autocrine and paracrine mechanisms. The renin-angiotensin system (RAS) is known to play a role in the activation of hepatic stellate cells and blocking the RAS attenuates hepatic fibrosis. We investigated the role of the RAS during extrahepatic cholestasis induced by bile duct ligation (BDL). In this study, we used normal and BDL rats that were treated with control, angiotensin II (ANG II), or losartan for 2 wk. In vitro studies were performed in a primary rat cholangiocyte cell line (NRIC). The expression of renin, angiotensin-converting enzyme, angiotensinogen, and angiotensin receptor type 1 was evaluated by immunohistochemistry (IHC), real-time PCR, and FACs and found to be increased in BDL compared with normal rat. The levels of ANG II were evaluated by ELISA and found to be increased in serum and conditioned media of cholangiocytes from BDL compared with normal rats. Treatment with ANG II increased biliary mass and proliferation in both normal and BDL rats. Losartan attenuated BDL-induced biliary proliferation. In vitro, ANG II stimulated NRIC proliferation via increased intracellular cAMP levels and activation of the PKA/ERK/CREB intracellular signaling pathway. ANG II stimulated a significant increase in Sirius red staining and IHC for fibronectin that was blocked by angiotensin receptor blockade. In vitro, ANG II stimulated the gene expression of collagen 1A1, fibronectin 1, and IL-6. These results indicate that cholangiocytes express a local RAS and that ANG II plays an important role in regulating biliary proliferation and fibrosis during extraheptic cholestasis.
No takes yet. Share an insight, caveat, or question.
Afroze et al. (2015) studied Extrahepatic cholestasis induced by bile duct ligation. Angiotensin II (ANG II) or Losartan vs. 0.9% NaCl (control) was evaluated on Biliary mass and proliferation (CK-19 and PCNA positive cholangiocytes) (p=<0.05). Angiotensin II stimulated biliary mass and proliferation in both normal and bile duct-ligated rats, while the angiotensin receptor blocker losartan attenuated bile duct ligation-induced biliary proliferation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: